FDA To Assess Anemia Drug Risks In Kidney Patients

Law360, New York (October 15, 2010, 10:59 AM EDT) -- A U.S. Food and Drug Administration advisory panel will meet on Monday to evaluate chronic kidney disease patients' use of popular anemia drugs made by Johnson & Johnson and Amgen Inc. and consider possible labeling and dosage changes, in light of new concerns about the drugs' health risks.

The purpose of the meeting, according to a draft briefing memo released Thursday, is to seek the advice of committee members on the benefit risk profile of eythropoiesis-stimulating agents, based on recent clinical test results that showed the...
To view the full article, register now.